Latest Vical Inc (VICL) Headlines Why Vical (VI
Post# of 17
Posted On: 03/13/2014 3:28:55 PM
Latest Vical Inc (VICL) Headlines
Why Vical (VICL) Might Be a Diamond in the Rough? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:46AM CDT
Vical has seen loss estimates narrowing over the past month and looks well positioned for a solid gain
Vical to Present at the ROTH Capital Partners 26th Annual Growth Stock Conference
GlobeNewswire - Wed Mar 05, 3:06PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Wednesday, March 12, at 8:30 a.m. PDT at the ROTH Capital Partners 26th Annual Growth Stock Conference (Newport Beach, California March 9 - 12). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
Vical to Present at the 34th Annual Cowen Health Care Conference
GlobeNewswire - Wed Feb 26, 3:09PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Monday, March 3, at 2:10 p.m. ET at the 34 Annual Cowen Health Care Conference (Boston, Massachusetts March 3 - 5).
Vical Q4 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 11:10AM CST
Vical's fourth quarter loss narrows
Hot Stock: Vical, Shares Gain 14.7% (VICL)
Comtex SmarTrend(R) - Wed Feb 12, 10:11AM CST
Vical (NASDAQ:VICL) is one of today's best performing low-priced stocks, up 14.7% to $1.56 on 1.6x average daily volume. Thus far today, Vical has traded 3.4 million shares, vs. average volume of 2.2 million shares per day. The stock has outperformed the Dow (14.7% to the Dow's -0.2%) and outperformed the S&P 500 (14.7% to the S&P's -0.0%) during today's trading.
Vical Reports 2013 Financial Results and Progress in Key Development Programs
GlobeNewswire - Wed Feb 12, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today reported financial results for the year ended December 31, 2013. The net loss for 2013 was $31.2 million, or $0.36 per share, compared with a net loss of $22.9 million, or $0.27 per share, for 2012. Revenues for 2013 were $7.7 million, compared with revenues of $17.5 million for 2012, reflecting lower payments from Astellas Pharma Inc. under an exclusive worldwide license of ASP0113, Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
The Global Gene Therapy Industry Has the Potential to Become a Multi-Million Dollar Industry by the End of 2017 Says Latest Offering
M2 - Mon Feb 10, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/j8sfvg/global_gene) has announced the addition of the "Global Gene Therapy Market Analysis" report to their offering. Gene therapy is the treatment of a disease by replacing, altering, or supplementing a gene that is absent or abnormal and whose absence or abnormality is causing the disease. It has evolved as one of the most sought after research objectives for difficult to cure' diseases. The gene therapy market in spite of presenting few marketable products and being nascent in terms of revenue generation holds tremendous growth potential. As per a new estimation carried out in our latest study, the global gene therapy industry has the potential to become a multi-million dollar industry by the end of 2017 as new products, especially those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth. According to the new research report, Global Gene Therapy Market Analysis, major focus has been made on the ongoing clinical trials for the development of innovative products. Majority trials are focused on oncology and they prove promising on global scale for US. In this context, the study provides a comprehensive overview of the various aspects of clinical trials in the gene therapy market such as phases, geographies, vector types etc. The report provides an in-depth and prudent analysis of the industry and research developments taking place at the global level. Primarily the market is presently dominated by oncology applications with several companies and academic institutions focusing on novel and difficult to treat' cancers. Other therapeutic areas seeing developments on gene therapy include cardiac conditions, genetic disorders and neurological diseases. An effective analysis of the key therapeutic areas has been included in the report. Companies Mentioned: - AnGes MG, Inc - Ark Therapeutics - Ceregene, Inc - Cobra Biologics - GenVec, Inc - Genzyme Corporation - Vical, Inc - Oxford BioMedica For more information visit http://www.researchandmarkets.com/research/j8...lobal_gene About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Vical to Present at the 2014 Leerink Global Healthcare Conference
GlobeNewswire - Fri Feb 07, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Thursday, February 13, at 3:30 p.m. ET at the 2014 Leerink Global Healthcare Conference (New York City, February 12 - 13).
Vical Announces News Release and Conference Call Schedule for 2013 Financial Results
GlobeNewswire - Wed Feb 05, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months and twelve months ended December 31, 2013, before the opening of trading on Wednesday, February 12, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Wednesday, February 12. The call is open on a listen-only basis to any interested parties. The company will provide details on independent and partnered development programs in the conference call and webcast.
Glu Mobile Adds an Arsenal of New Titles to Give â??Deer Hunter' Company: Glu Mobile Inc. (NASDAQ: GLUU), Aeterna Zentaris Inc. (NASDAQ: AEZS), Vical Inc. (NASDAQ:VICL), Delcath Systems Inc. (NASDAQ: DCTH)
ACCESSWIRE - Tue Jan 28, 10:04AM CST
When smartphones meet free-to-play games it creates a business model that game maker Glu Mobile Inc. (NASDAQ: GLUU) is exploiting to the hilt.
5 Stocks With Big Insider Buying
at The Street - Wed Jan 15, 12:44PM CST
Insiders at these companies have been scooping up shares of their own stocks lately.
Vical Incorporated (VICL) Jumps: Stock Up 14.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 8:39AM CST
Vical Incorporated was a big mover last session, as its shares rose almost 15% on the day.
5 Stocks Poised for Breakouts
at The Street - Fri Jan 10, 12:20PM CST
These stocks look ready to break out and trade higher from current levels.
New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
Hot Stock: Vical, Shares Gain 5.8% (VICL)
Comtex SmarTrend(R) - Mon Jan 06, 10:13AM CST
Vical (NASDAQ:VICL) is one of today's best performing low-priced stocks, up 5.8% to $1.28 on 1.2x average daily volume. Thus far today, Vical has traded 1.5 million shares, vs. average volume of 1.2 million shares per day. The stock has outperformed the Dow (5.8% to the Dow's -0.1%) and outperformed the S&P 500 (5.8% to the S&P's -0.2%) during today's trading.
Vical Incorporated begins Phase 1/2 trial of therapeutic HSV-2 vaccine for recurrent genital herpes
M2 - Wed Dec 18, 4:43AM CST
Biopharmaceutical products company Vical Incorporated (NasdaqGS:VICL) revealed on Tuesday the launch of its Phase 1/2 trial of its Vaxfectin-formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2), a cause of genital herpes.
The Worst Biotech CEO of 2013 Is...
at The Street - Tue Dec 17, 6:58AM CST
Vical's Vijay Samant is this year's CEO loser by a wide margin.
Vical Announces Initiation of Phase 1/2 Trial of a Therapeutic HSV-2 Vaccine for Genital Herpes
GlobeNewswire - Tue Dec 17, 6:00AM CST
Vical Incorporated (Nasdaq:VICL) today announced the initiation of its Phase 1/2 trial of the company's Vaxfectin(TM)-formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2), a cause of genital herpes, in approximately 156 subjects. The randomized, double-blind, placebo-controlled trial will evaluate safety, tolerability and efficacy in otherwise healthy HSV-2- infected patients aged 18 to 50 years at six key U.S. clinical sites.
Why Vical (VICL) Might Be a Diamond in the Rough? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:46AM CDT
Vical has seen loss estimates narrowing over the past month and looks well positioned for a solid gain
Vical to Present at the ROTH Capital Partners 26th Annual Growth Stock Conference
GlobeNewswire - Wed Mar 05, 3:06PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Wednesday, March 12, at 8:30 a.m. PDT at the ROTH Capital Partners 26th Annual Growth Stock Conference (Newport Beach, California March 9 - 12). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
Vical to Present at the 34th Annual Cowen Health Care Conference
GlobeNewswire - Wed Feb 26, 3:09PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Monday, March 3, at 2:10 p.m. ET at the 34 Annual Cowen Health Care Conference (Boston, Massachusetts March 3 - 5).
Vical Q4 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 11:10AM CST
Vical's fourth quarter loss narrows
Hot Stock: Vical, Shares Gain 14.7% (VICL)
Comtex SmarTrend(R) - Wed Feb 12, 10:11AM CST
Vical (NASDAQ:VICL) is one of today's best performing low-priced stocks, up 14.7% to $1.56 on 1.6x average daily volume. Thus far today, Vical has traded 3.4 million shares, vs. average volume of 2.2 million shares per day. The stock has outperformed the Dow (14.7% to the Dow's -0.2%) and outperformed the S&P 500 (14.7% to the S&P's -0.0%) during today's trading.
Vical Reports 2013 Financial Results and Progress in Key Development Programs
GlobeNewswire - Wed Feb 12, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today reported financial results for the year ended December 31, 2013. The net loss for 2013 was $31.2 million, or $0.36 per share, compared with a net loss of $22.9 million, or $0.27 per share, for 2012. Revenues for 2013 were $7.7 million, compared with revenues of $17.5 million for 2012, reflecting lower payments from Astellas Pharma Inc. under an exclusive worldwide license of ASP0113, Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
The Global Gene Therapy Industry Has the Potential to Become a Multi-Million Dollar Industry by the End of 2017 Says Latest Offering
M2 - Mon Feb 10, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/j8sfvg/global_gene) has announced the addition of the "Global Gene Therapy Market Analysis" report to their offering. Gene therapy is the treatment of a disease by replacing, altering, or supplementing a gene that is absent or abnormal and whose absence or abnormality is causing the disease. It has evolved as one of the most sought after research objectives for difficult to cure' diseases. The gene therapy market in spite of presenting few marketable products and being nascent in terms of revenue generation holds tremendous growth potential. As per a new estimation carried out in our latest study, the global gene therapy industry has the potential to become a multi-million dollar industry by the end of 2017 as new products, especially those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth. According to the new research report, Global Gene Therapy Market Analysis, major focus has been made on the ongoing clinical trials for the development of innovative products. Majority trials are focused on oncology and they prove promising on global scale for US. In this context, the study provides a comprehensive overview of the various aspects of clinical trials in the gene therapy market such as phases, geographies, vector types etc. The report provides an in-depth and prudent analysis of the industry and research developments taking place at the global level. Primarily the market is presently dominated by oncology applications with several companies and academic institutions focusing on novel and difficult to treat' cancers. Other therapeutic areas seeing developments on gene therapy include cardiac conditions, genetic disorders and neurological diseases. An effective analysis of the key therapeutic areas has been included in the report. Companies Mentioned: - AnGes MG, Inc - Ark Therapeutics - Ceregene, Inc - Cobra Biologics - GenVec, Inc - Genzyme Corporation - Vical, Inc - Oxford BioMedica For more information visit http://www.researchandmarkets.com/research/j8...lobal_gene About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Vical to Present at the 2014 Leerink Global Healthcare Conference
GlobeNewswire - Fri Feb 07, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Thursday, February 13, at 3:30 p.m. ET at the 2014 Leerink Global Healthcare Conference (New York City, February 12 - 13).
Vical Announces News Release and Conference Call Schedule for 2013 Financial Results
GlobeNewswire - Wed Feb 05, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months and twelve months ended December 31, 2013, before the opening of trading on Wednesday, February 12, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Wednesday, February 12. The call is open on a listen-only basis to any interested parties. The company will provide details on independent and partnered development programs in the conference call and webcast.
Glu Mobile Adds an Arsenal of New Titles to Give â??Deer Hunter' Company: Glu Mobile Inc. (NASDAQ: GLUU), Aeterna Zentaris Inc. (NASDAQ: AEZS), Vical Inc. (NASDAQ:VICL), Delcath Systems Inc. (NASDAQ: DCTH)
ACCESSWIRE - Tue Jan 28, 10:04AM CST
When smartphones meet free-to-play games it creates a business model that game maker Glu Mobile Inc. (NASDAQ: GLUU) is exploiting to the hilt.
5 Stocks With Big Insider Buying
at The Street - Wed Jan 15, 12:44PM CST
Insiders at these companies have been scooping up shares of their own stocks lately.
Vical Incorporated (VICL) Jumps: Stock Up 14.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 8:39AM CST
Vical Incorporated was a big mover last session, as its shares rose almost 15% on the day.
5 Stocks Poised for Breakouts
at The Street - Fri Jan 10, 12:20PM CST
These stocks look ready to break out and trade higher from current levels.
New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
Hot Stock: Vical, Shares Gain 5.8% (VICL)
Comtex SmarTrend(R) - Mon Jan 06, 10:13AM CST
Vical (NASDAQ:VICL) is one of today's best performing low-priced stocks, up 5.8% to $1.28 on 1.2x average daily volume. Thus far today, Vical has traded 1.5 million shares, vs. average volume of 1.2 million shares per day. The stock has outperformed the Dow (5.8% to the Dow's -0.1%) and outperformed the S&P 500 (5.8% to the S&P's -0.2%) during today's trading.
Vical Incorporated begins Phase 1/2 trial of therapeutic HSV-2 vaccine for recurrent genital herpes
M2 - Wed Dec 18, 4:43AM CST
Biopharmaceutical products company Vical Incorporated (NasdaqGS:VICL) revealed on Tuesday the launch of its Phase 1/2 trial of its Vaxfectin-formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2), a cause of genital herpes.
The Worst Biotech CEO of 2013 Is...
at The Street - Tue Dec 17, 6:58AM CST
Vical's Vijay Samant is this year's CEO loser by a wide margin.
Vical Announces Initiation of Phase 1/2 Trial of a Therapeutic HSV-2 Vaccine for Genital Herpes
GlobeNewswire - Tue Dec 17, 6:00AM CST
Vical Incorporated (Nasdaq:VICL) today announced the initiation of its Phase 1/2 trial of the company's Vaxfectin(TM)-formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2), a cause of genital herpes, in approximately 156 subjects. The randomized, double-blind, placebo-controlled trial will evaluate safety, tolerability and efficacy in otherwise healthy HSV-2- infected patients aged 18 to 50 years at six key U.S. clinical sites.
(0)
(0)Fresh Tracks Therapeutics, Inc. (FRTX) Stock Research Links
Scroll down for more posts ▼